Positive Patient Stories™

Investor Overview

Webcast ImageWebcast - Replay
Fourth Quarter and Fiscal Year 2018 Earnings Call
02/27/19 at 4:30 p.m. ET
Fourth Quarter and Fiscal Year 2018 Earnings Call
Wednesday, February 27, 2019 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
8th Annual SVB Leerink Global Healthcare Conference
02/28/19 at 1:00 p.m. ET
8th Annual SVB Leerink Global Healthcare Conference
Thursday, February 28, 2019 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Paratek Pharmaceuticals Presentation at the Cowen and Company 39th Annual Health Care Conference
03/13/19 at 10:00 a.m. ET
Paratek Pharmaceuticals Presentation at the Cowen and Company 39th Annual Health Care Conference
Wednesday, March 13, 2019 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company’s lead FDA approved commercial product, NUZYRA™ (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens. Paratek is also studying NUZYRA™ for the treatment of urinary tract infections (UTI).

Paratek has submitted a marketing authorization application for omadacycline in the European Union. Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.

SEYSARA™ (sarecycline) is an FDA-approved product with respect to which we have exclusively licensed in the United States certain rights to Almirall, LLC, or Almirall. SEYSARA is currently being marketed by Almirall in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek retains development and commercialization rights with respect to sarecycline in the rest of the world.

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.71
Change (%) Stock is Down 0.06 (1.04%)
Volume403,255
Data as of 03/25/19 4:00 p.m. ET

Latest News

03/18/19
Paratek Pharmaceuticals Announces Management Change
03/01/19
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
03/01/19
Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
02/27/19
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.